The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use

blonca9
Sep 23, 2024
1 min read

Patrick Amstutz discusses the properties of DARPins that make them ideal building blocks of multispecifics and use cases such as immuno oncology and radiotherapies.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight